Sunitinib, a multitarget tyrosine kinase inhibitor that targets PDGFR, VEGFR, KIT, FLT-3 and RET, can inhibit not only tumor proliferation but also angiogenesis at the same time. This evidence concerns the gene KDR and neoplasm.